Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $185.0 million.

  • UroGen Pharma's Liabilities and Shareholders Equity fell 3871.49% to $185.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.1 million, marking a year-over-year decrease of 369.65%. This contributed to the annual value of $285.7 million for FY2024, which is 6023.18% up from last year.
  • Per UroGen Pharma's latest filing, its Liabilities and Shareholders Equity stood at $185.0 million for Q3 2025, which was down 3871.49% from $208.7 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Liabilities and Shareholders Equity registered a high of $301.9 million during Q3 2024, and its lowest value of $95.4 million during Q2 2023.
  • Over the past 5 years, UroGen Pharma's median Liabilities and Shareholders Equity value was $165.7 million (recorded in 2022), while the average stood at $177.5 million.
  • As far as peak fluctuations go, UroGen Pharma's Liabilities and Shareholders Equity plummeted by 4164.35% in 2021, and later soared by 19556.0% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Liabilities and Shareholders Equity stood at $119.7 million in 2021, then rose by 13.26% to $135.6 million in 2022, then surged by 31.48% to $178.3 million in 2023, then surged by 60.23% to $285.7 million in 2024, then tumbled by 35.23% to $185.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $185.0 million for Q3 2025, versus $208.7 million for Q2 2025 and $247.6 million for Q1 2025.